Brown, Lisle/Cummings, Inc. Astrazeneca PLC Transaction History
Brown, Lisle/Cummings, Inc.
- $329 Billion
- Q3 2024
A detailed history of Brown, Lisle/Cummings, Inc. transactions in Astrazeneca PLC stock. As of the latest transaction made, Brown, Lisle/Cummings, Inc. holds 908 shares of AZN stock, worth $60,200. This represents 0.02% of its overall portfolio holdings.
Number of Shares
908
Previous 908
-0.0%
Holding current value
$60,200
Previous $70.8 Million
0.1%
% of portfolio
0.02%
Previous 0.02%
Shares
5 transactions
Others Institutions Holding AZN
# of Institutions
1,361Shares Held
475MCall Options Held
5.39MPut Options Held
3.75M-
Price T Rowe Associates Inc Baltimore, MD62.9MShares$4.17 Billion0.56% of portfolio
-
Primecap Management CO Pasadena, CA42MShares$2.78 Billion2.45% of portfolio
-
Wellington Management Group LLP Boston, MA37.2MShares$2.47 Billion0.52% of portfolio
-
Capital International Investors Los Angeles, CA36.8MShares$2.44 Billion0.57% of portfolio
-
Franklin Resources Inc San Mateo, CA19.1MShares$1.27 Billion0.45% of portfolio
About ASTRAZENECA PLC
- Ticker AZN
- Exchange OTC
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 3,099,020,032
- Market Cap $205B
- Description
- AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...